FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034615397> ?p ?o ?g. }

• W3034615397 endingPage "901" @default.
• W3034615397 startingPage "900" @default.
• W3034615397 abstract "Marone and Rinaldi1Marone E.M. Rinaldi L.F. Upsurge of deep venous thrombosis in patients affected by COVID-19: preliminary data and possible explanations.J Vasc Surg Venous Lymphat Disord. 2020; 8: 694-695Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar in their study reported cases of deep venous thrombosis (DVT) in hospitalized patients with 2019 novel coronavirus disease (COVID-19). We appreciate the efforts by the authors to present preliminary data on COVID-19-related DVT in their practicing institution and to discuss the possible underlying mechanisms of DVT. According to the authors, administration of anticoagulant/therapeutic doses of low-molecular-weight heparin (LMWH) in hospitalized COVID-19 patients, instead of prophylactic doses, is the current practice in their practicing institution. Although some may have concern of increased risk of bleeding, bleeding does not appear to be a major manifestation of COVID-19. A higher than traditional standard prophylactic dose of LMWH as adopted in the authors' institution should be encouraged because there is possibly more risk of venous thromboembolism in hospitalized COVID-19 patients than in their non-COVID-19 counterparts. Particularly, Middeldorp et al2Middeldorp S. Coppens M. van Haaps T.F. Foppen M. Vlaar A.P. Müller M.C. et al.Incidence of venous thromboembolism in hospitalized patients with COVID-19.J Thromb Haemost. 2020 May 5; ([Epub ahead of print])Crossref PubMed Scopus (1037) Google Scholar reported that about 20% of the included COVID-19 patients had venous thromboembolism despite routine thromboprophylaxis with prophylactic doses of LMWH. A comparison with the largest randomized controlled trial thus far of LMWH for the prevention of venous thromboembolism in acutely ill medical patients (non-COVID-19) that reported a thromboprophylaxis failure rate of only 2.77% indicated that the standard prophylactic dose of LMWH in COVID-19 patients may be inadequate. A higher than usual rate of thromboprophylaxis failure may be due to an increasingly recognized hypercoagulable state with COVID-19 in which a number of changes in circulating prothrombotic factors have been reported in COVID-19 patients: elevated factor VIII level, elevated fibrinogen level, circulating prothrombotic microparticles, and presence of neutrophil extracellular traps.3Ranucci M. Ballotta A. Di Dedda U. Bayshnikova E. Dei Poli M. Resta M. et al.The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome.J Thromb Haemost. 2020; 18: 1747-1751Crossref PubMed Scopus (659) Google Scholar,4Panigada M. Bottino N. Tagliabue P. Grasselli G. Novembrino C. Chantarangkul V. et al.Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis.J Thromb Haemost. 2020; 18: 1738-1742Crossref PubMed Scopus (896) Google Scholar These prothrombotic changes are not usually detected in acutely ill medical patients without COVID-19, in whom the efficacy of standard prophylactic dosing of LMWH is established. In addition, it has become increasingly clear that obesity is one of the biggest risk factors for severe COVID-19 disease, and therefore obese patients may constitute a significant proportion of hospitalized COVID-19 patients.5Caussy C. Wallet F. Laville M. Disse E. Obesity is associated with severe forms of COVID-19.Obesity (Silver Spring). 2020; 28: 1175Crossref PubMed Scopus (123) Google Scholar Because high body weight correlates with low anti-factor Xa levels, an anti-factor Xa-guided individualized dosing approach with LMWH may also be adopted in the obese hospitalized COVID-19 population to further reduce the risk of thromboprophylaxis failure. We look forward to studies reporting outcomes on anti-factor Xa-guided approach for dosing of LMWH among COVID-19 patients. ReplyJournal of Vascular Surgery: Venous and Lymphatic DisordersVol. 8Issue 5PreviewThe remarks made by Kow and Hasan1 regarding the use of low-molecular-weight heparin (LMWH) in hospitalized COVID-19 patients are greatly appreciated since they focus on one of the most important aspects concerning the treatment of this disease, namely, thromboprophylaxis. In fact, since our latest letter was published in this Journal, suggesting a close correlation between COVID-19 and deep venous thrombosis (DVT),2 a number of studies have followed, confirming this view and providing evidence of the fact that respiratory infection is also responsible for a systemic procoagulant activity,3-5 which can lead to different clinical manifestations ranging from DVT to septic intravascular coagulation, not only in the most critical cases (patients in intensive care unit) but in all in-hospital patients. Full-Text PDF" @default.
• W3034615397 created "2020-06-19" @default.
• W3034615397 creator A5070482896 @default.
• W3034615397 creator A5076366979 @default.
• W3034615397 date "2020-09-01" @default.
• W3034615397 modified "2023-10-11" @default.
• W3034615397 title "Use of low-molecular-weight heparin in COVID-19 patients" @default.
• W3034615397 cites W3016595631 @default.
• W3034615397 cites W3016641669 @default.
• W3034615397 cites W3016822501 @default.
• W3034615397 cites W3016965546 @default.
• W3034615397 cites W3017081690 @default.
• W3034615397 doi "https://doi.org/10.1016/j.jvsv.2020.06.006" @default.
• W3034615397 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7297673" @default.
• W3034615397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32561464" @default.
• W3034615397 hasPublicationYear "2020" @default.
• W3034615397 type Work @default.
• W3034615397 sameAs 3034615397 @default.
• W3034615397 citedByCount "23" @default.
• W3034615397 countsByYear W30346153972020 @default.
• W3034615397 countsByYear W30346153972021 @default.
• W3034615397 countsByYear W30346153972022 @default.
• W3034615397 crossrefType "journal-article" @default.
• W3034615397 hasAuthorship W3034615397A5070482896 @default.
• W3034615397 hasAuthorship W3034615397A5076366979 @default.
• W3034615397 hasBestOaLocation W30346153971 @default.
• W3034615397 hasConcept C120665830 @default.
• W3034615397 hasConcept C121332964 @default.
• W3034615397 hasConcept C126322002 @default.
• W3034615397 hasConcept C17744445 @default.
• W3034615397 hasConcept C177713679 @default.
• W3034615397 hasConcept C199539241 @default.
• W3034615397 hasConcept C2776265017 @default.
• W3034615397 hasConcept C2776884760 @default.
• W3034615397 hasConcept C2777557582 @default.
• W3034615397 hasConcept C2778205648 @default.
• W3034615397 hasConcept C2779134260 @default.
• W3034615397 hasConcept C2779473830 @default.
• W3034615397 hasConcept C2780011451 @default.
• W3034615397 hasConcept C2780868729 @default.
• W3034615397 hasConcept C2991741193 @default.
• W3034615397 hasConcept C3008058167 @default.
• W3034615397 hasConcept C524204448 @default.
• W3034615397 hasConcept C61511704 @default.
• W3034615397 hasConcept C71924100 @default.
• W3034615397 hasConcept C83867959 @default.
• W3034615397 hasConceptScore W3034615397C120665830 @default.
• W3034615397 hasConceptScore W3034615397C121332964 @default.
• W3034615397 hasConceptScore W3034615397C126322002 @default.
• W3034615397 hasConceptScore W3034615397C17744445 @default.
• W3034615397 hasConceptScore W3034615397C177713679 @default.
• W3034615397 hasConceptScore W3034615397C199539241 @default.
• W3034615397 hasConceptScore W3034615397C2776265017 @default.
• W3034615397 hasConceptScore W3034615397C2776884760 @default.
• W3034615397 hasConceptScore W3034615397C2777557582 @default.
• W3034615397 hasConceptScore W3034615397C2778205648 @default.
• W3034615397 hasConceptScore W3034615397C2779134260 @default.
• W3034615397 hasConceptScore W3034615397C2779473830 @default.
• W3034615397 hasConceptScore W3034615397C2780011451 @default.
• W3034615397 hasConceptScore W3034615397C2780868729 @default.
• W3034615397 hasConceptScore W3034615397C2991741193 @default.
• W3034615397 hasConceptScore W3034615397C3008058167 @default.
• W3034615397 hasConceptScore W3034615397C524204448 @default.
• W3034615397 hasConceptScore W3034615397C61511704 @default.
• W3034615397 hasConceptScore W3034615397C71924100 @default.
• W3034615397 hasConceptScore W3034615397C83867959 @default.
• W3034615397 hasIssue "5" @default.
• W3034615397 hasLocation W30346153971 @default.
• W3034615397 hasLocation W30346153972 @default.
• W3034615397 hasLocation W30346153973 @default.
• W3034615397 hasOpenAccess W3034615397 @default.
• W3034615397 hasPrimaryLocation W30346153971 @default.
• W3034615397 hasRelatedWork W2062272588 @default.
• W3034615397 hasRelatedWork W2197337485 @default.
• W3034615397 hasRelatedWork W220073818 @default.
• W3034615397 hasRelatedWork W2319335038 @default.
• W3034615397 hasRelatedWork W2379972596 @default.
• W3034615397 hasRelatedWork W2411696557 @default.
• W3034615397 hasRelatedWork W2418035153 @default.
• W3034615397 hasRelatedWork W2512765918 @default.
• W3034615397 hasRelatedWork W3146056168 @default.
• W3034615397 hasRelatedWork W33323292 @default.
• W3034615397 hasVolume "8" @default.
• W3034615397 isParatext "false" @default.
• W3034615397 isRetracted "false" @default.
• W3034615397 magId "3034615397" @default.
• W3034615397 workType "article" @default.